Systemic lupus erythematosus in 2013: Taking a closer look at biologic therapy for SLE

Nature Reviews Rheumatology

Volumn 10, Issue 2, 2014, Pages 71-72

  Isenberg, David A ^a   Rahman, Anisur ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL THERAPY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84895110569     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.203     Document Type: Review

References (10)

1. Eder, L., Urowitz, M. B. & Gladman, D. D. Damage in lupus patients - what have we learned so far? Lupus 22, 1225-1231 (2013).
2. Rahman, P., Gladman, D. D., Urowitz, M. B., Hallett, D. & Tam, L. S. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93-96 (2001).
3. Condon, M. B. et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72, 1280-1286 (2013).
4. Ezeonyeji, A. N. & Isenberg, D. A. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 51, 476-481 (2012).
5. Merrill, J. T. et al. Efficacy and safety of rituximab in moderatelytoseverely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222-233 (2010).
6. Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215-1226 (2012).
7. Bosma, A., Abdel-Gadir, A., Isenberg, D. A., Jury, E. C. & Mauri, C. Lipid-antigen presentation by CD1d+ B cells is essential for the maintenance of invariant natural killer T cells. Immunity 36, 477-490 (2012).
8. Wofsy, D., Hillson, J. L. & Diamond, B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 65, 1586-1591 (2013).
9. Kandala, N. B. et al. Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open 3, e002852 (2013).
10. Wallace, D. J. et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. http://dx.doi.org/1136/annrheumdis-2012-202760